JP2004502785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502785A5 JP2004502785A5 JP2002509459A JP2002509459A JP2004502785A5 JP 2004502785 A5 JP2004502785 A5 JP 2004502785A5 JP 2002509459 A JP2002509459 A JP 2002509459A JP 2002509459 A JP2002509459 A JP 2002509459A JP 2004502785 A5 JP2004502785 A5 JP 2004502785A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- inner ear
- cells
- use according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003027 ear inner Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 239000013043 chemical agent Substances 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 7
- 210000002768 hair cell Anatomy 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 2
- 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 2
- 102100033269 Cyclin-dependent kinase inhibitor 1C Human genes 0.000 description 2
- 101710153652 Cyclin-dependent kinase inhibitor 1C Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61409900A | 2000-07-11 | 2000-07-11 | |
| PCT/US2001/021793 WO2002004605A2 (en) | 2000-07-11 | 2001-07-10 | Stimulation of cellular regeneration and differentiation in the inner ear |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502785A JP2004502785A (ja) | 2004-01-29 |
| JP2004502785A5 true JP2004502785A5 (enExample) | 2008-09-04 |
Family
ID=24459860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002509459A Pending JP2004502785A (ja) | 2000-07-11 | 2001-07-10 | 内耳における細胞の再生および分化の刺激 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1307542A2 (enExample) |
| JP (1) | JP2004502785A (enExample) |
| KR (1) | KR100896489B1 (enExample) |
| CN (1) | CN1441841B (enExample) |
| AU (2) | AU2001288219C1 (enExample) |
| CA (1) | CA2412764C (enExample) |
| WO (1) | WO2002004605A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745209B2 (en) | 2005-07-26 | 2010-06-29 | Corning Incorporated | Multilayered cell culture apparatus |
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| US20080176318A1 (en) | 2006-12-07 | 2008-07-24 | Wilson John R | Highly efficient devices and methods for culturing cells |
| DE102010007281A1 (de) * | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
| AU2012289865A1 (en) * | 2011-08-03 | 2014-02-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide compounds for treating hearing and balance disorders |
| EP2802657B1 (en) | 2012-01-12 | 2018-05-02 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
| AU2013312358B2 (en) | 2012-09-07 | 2018-08-09 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CN109219439B (zh) * | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| CN114736924B (zh) * | 2021-01-07 | 2024-11-22 | 中国科学院脑科学与智能技术卓越创新中心 | 异位联合过表达Atoh1和Ikzf2再生耳蜗外毛细胞及其应用 |
| JP7760144B2 (ja) * | 2021-04-21 | 2025-10-27 | 学校法人順天堂 | 内耳細胞の製造法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593290B1 (en) * | 1996-11-01 | 2003-07-15 | Genentech, Inc. | Treatment of inner ear hair cells |
| WO2000023084A1 (en) * | 1998-10-21 | 2000-04-27 | Jonathan Kil | Methods for stimulating the regeneration of inner ear cells |
| DE19807426A1 (de) * | 1998-02-23 | 1999-10-14 | Otogene Biotechnologische Fors | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
-
2001
- 2001-07-10 CA CA2412764A patent/CA2412764C/en not_active Expired - Lifetime
- 2001-07-10 WO PCT/US2001/021793 patent/WO2002004605A2/en not_active Ceased
- 2001-07-10 KR KR1020037000388A patent/KR100896489B1/ko not_active Expired - Fee Related
- 2001-07-10 JP JP2002509459A patent/JP2004502785A/ja active Pending
- 2001-07-10 AU AU2001288219A patent/AU2001288219C1/en not_active Ceased
- 2001-07-10 CN CN018126065A patent/CN1441841B/zh not_active Expired - Lifetime
- 2001-07-10 EP EP01967939A patent/EP1307542A2/en not_active Withdrawn
- 2001-07-10 AU AU8821901A patent/AU8821901A/xx active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11242532B2 (en) | Self-assembled 3D RNA cage nanoparticles | |
| JP2020094063A5 (enExample) | ||
| CA2565103C (en) | Peptide conjugated, inosine-substituted antisense oligomer compound and method | |
| JP2004502785A5 (enExample) | ||
| WO2001030965A3 (en) | Methods of in vivo gene transfer using a sleeping beauty transposon system | |
| CA2520541A1 (en) | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | |
| JP2005500025A5 (enExample) | ||
| IL182362A0 (en) | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin | |
| JP2009514877A5 (enExample) | ||
| JP2015523082A5 (enExample) | ||
| WO2007018544A3 (en) | Tri-block copolymers for nanosphere-based drug delivery | |
| CA2416492A1 (en) | Treatment of glycogen storage disease type ii | |
| EP1283054A4 (en) | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF | |
| EP2392660A3 (en) | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor | |
| WO2007031319A8 (en) | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides | |
| EP3246403A3 (en) | Rationally designed meganucleases with altered sequence specificity and dna-binding affinity | |
| WO2000042561A3 (en) | Oligonucleotide mediated nucleic acid recombination | |
| JP2006500958A5 (enExample) | ||
| WO2001080896A3 (en) | Flavopiridol drug combinations and methods with reduced side effects | |
| JP2018533956A5 (enExample) | ||
| WO2003099225A3 (en) | Compositions for delivering nucleic acids to cells | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| JP2010532163A5 (enExample) | ||
| WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor |